Introduction: This study aimed to analyze differences in sharing of prescription analgesics between rural and urban populations.
Methods: We surveyed 1000 participants in outpatient family medicine settings in Croatia. We used a 35-item questionnaire to analyze patients' characteristics, pain intensity, prescription analgesic sharing behavior, and perception of risks regarding sharing prescription medications.
Results: Prescription analgesic sharing was significantly more frequent in the rural (64%) than in the urban population 55% ( = 0.01). Participants from rural areas more commonly asked for verbal or written information than those from urban areas when taking others' prescription analgesics ( < 0.001) or giving such analgesics ( < 0.001). Participants from rural areas more commonly informed their physician about such behavior compared to those from urban areas ( < 0.01), and they were significantly more often asked about such behavior by their physician (p < 0.01). Perceptions about risks associated with sharing prescription medication were similar between rural and urban populations.
Conclusions: There are systematic differences in the frequency of prescription analgesics and associated behaviors between patients in family medicine who live in rural and urban areas. Patients from rural areas were more prone to share prescription analgesics. Future studies should examine reasons for differences in sharing prescription analgesics between rural and urban areas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148597 | PMC |
http://dx.doi.org/10.3390/healthcare9050541 | DOI Listing |
Pharmacoepidemiol Drug Saf
January 2025
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA.
Purpose: Long-term opioid therapy (LTOT) has been shown to be associated with opioid overdose, but the definition of LTOT varies widely across studies. We use a rigorous LTOT definition to examine risk of opioid overdose by duration of treatment.
Methods: Data were from a large private health insurance provider in North Carolina linked to mortality records from 2006-2018.
J Am Med Dir Assoc
January 2025
EPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France; Université de Versailles Saint-Quentin-en-Yvelines, France.
Objective: We aimed to describe the medications prescribed to people aged ≥90 years.
Design: A cohort study was performed using data from the year 2022.
Setting And Participants: Using data from the French National Health Data System, people aged ≥90 years affiliated with the general insurance scheme were included.
J Chiropr Med
March 2024
Department of Basic Medical Sciences, Durban University of Technology, Durban, KwaZulu-Natal, South Africa.
Objectives: The purpose of this study was to identify the prevalence of chronic musculoskeletal pain (CMSP) and analgesic self-medication. The knowledge and practices of those who self-medicate with analgesics and factors influencing this was also ascertained.
Methods: This study was a quantitative, descriptive cross-sectional study.
Bone Jt Open
January 2025
Division of Trauma & Orthopaedic Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.
Aims: The primary aim of this study is to compare mobility status of patients receiving oral oxycodone with those receiving subcutaneous alfentanil as analgesic methods prior to mobilization to help physiotherapy compliance after hip fracture surgery. The secondary aims are to assess postoperative pain, health-related quality of life, in-hospital length of stay, total use of analgesia over postoperative days 1 and 2 (POD 1 and POD 2), complication rates within 30 days, and 30-day mortality rates.
Methods: A single-centre, prospective cohort study of 64 patients will be undertaken.
Allergol Immunopathol (Madr)
January 2025
Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
Rheumatoid arthritis (RA) is a chronic autoimmune joint disease. Its main pathological manifestations are joint cartilage, bone tissue injury, synovial hyperplasia, and chronic inflammation. At present, the pathogenesis of the disease has not been fully defined, and delaying the disease to improve joint function is the existing treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!